Evaluation of a Noninvasive Fetal RHD Genotyping Test

Sequenom, Inc.500 enrolled

Overview

This study will collect whole blood samples from pregnant subjects who are RhD negative by serology to develop an assay for RHD determination of the fetus.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Rhesus D Genotype

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is 18-64 years of age * Subject is female * Subject is pregnant * Subject is RhD negative * Subject is between 10 and 28 weeks gestation * Subject provides informed consent * Subject agrees to provide neonatal RHD and sex outcome Exclusion Criteria: * None

Locations (5)

Sharp Grossmont Hospital

San Diego, California, United States

West Coast OBGYN

San Diego, California, United States

Women's Health Care, Inc

San Diego, California, United States

Scripps Hospitals (5 San Diego locations)

San Diego, California, United States

Outcomes

Primary Outcomes

Fetal RHD determination from maternal whole blood

Time frame: Between 10 and 28 weeks gestation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.